trending Market Intelligence /marketintelligence/en/news-insights/trending/5bre5ysppcuedhhaorek7g2 content esgSubNav
In This List

Boston Scientific to buy privately held Augmenix for up to $600M

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Boston Scientific to buy privately held Augmenix for up to $600M

Boston Scientific Corp. agreed to buy privately held Augmenix, Inc. for $500 million in cash plus up to $100 million in sales-based milestone payments.

Bedford, Mass.-based Augmenix makes the SpaceOAR System, a medical device used to reduce side effects resulting from prostate cancer radiotherapy.

Prostate cancer radiotherapy can lead to high radiation exposure to the rectum due to its proximity to the prostate.

SpaceOAR involves injecting a compound through minimal surgical incisions to create additional space between the rectum and prostate, thus reducing radiation exposure.

The product is expected to record sales of $50 million in 2018, and close to $90 million in 2019, Marlborough, Mass.-based Boston Scientific said in a Sept. 6 release.

The maker of heart stents and pacemakers added that more than 1.1 million men are diagnosed with prostate cancer worldwide every year, with about 400,000 men expected to undergo radiotherapy.

Boston Scientific said the transaction is expected to be immaterial to its adjusted EPS in 2018 and 2019, but will add to its earnings starting in 2020. The deal is set to close in the fourth quarter of 2018.